§ Federal grant opportunity · HT942526ORPARA
DoW Orthopaedic, Applied Research Award
Teresa M Parker-Reeser Grants Officer is accepting applications for DoW Orthopaedic, Applied Research Award. The deadline is November 18, 2026 and the published award range is Award amount not published.
Key facts
- Funder
- Teresa M Parker-Reeser Grants Officer
- Application deadline
- November 18, 2026
- Award range
- Award amount not published
- Eligibility
- Eligibility criteria are published in the funding opportunity announcement.
- Geography
- United States
- Focus areas
- Research
- Opportunity number
- HT942526ORPARA
Program overview
Summary: The Orthopaedic Research Program (ORP) Applied Research Award (ARA) seeks applied research applications focused on advancing optimal treatment and restoration of function for individuals with orthopaedic injuries sustained during combat or service-related activities. Distinctive Features: • Applied research is defined as work that refines concepts and ideas into potential solutions with a view toward evaluating technical feasibility of promising new knowledge products, pharmacologic agents, behavioral and rehabilitation interventions, diagnostic and therapeutic techniques, clinical guidance and/or emerging approaches and technologies. • Preliminary data is required. • Military relevance : the ORP expects that research findings benefit Service Members, their families, Veterans and the general public. • Clinical research is not allowed.
How to apply
- Confirm your organization meets the eligibility criteria above.
- Read the full funding opportunity announcement from Teresa M Parker-Reeser Grants Officer.
- Draft your narrative against the funder's stated priorities and review criteria.
- Submit before November 18, 2026, allowing time for registration and validation.
Related grant opportunities
- DoW Rare Cancers Resource and Community Development Award
- NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (UG3/UH3 Clinical Trial Optional)
- Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)
- DoW Toxic Exposures Clinical Trial Award
- DoW Toxic Exposures Investigator Initiated Research Award
Find every grant your organization qualifies for
Mavenly scores this opportunity against your mission, geography, and funding history — then drafts the proposal with you and tracks the deadline through submission and reporting.